IGM-2323 – High Avidity IgM-Based CD20xCD3 Bispecific Antibody for Enhanced T Cell Dependent Killing with Minimal Cytokine Release

Time: 11:30 am
day: Focus Day Track B - AM


  • Outlining current state of bispecific antibodies that are largely based on IgGlike scaffolds
  • Providing provide high avidity binding to CD20, an scFv fused to the N-terminus of J-chain to provide monovalent engagement of CD3 on T-cells and HSA fused to the C-terminus of J-chain to improve pharmacokinetics
  • Demonstrating preclinical IGM-2323 data is highly effective at complement-dependent cytotoxicity and T-cell dependent cellular cytotoxicity killing of tumor cells with minimal cytokine release